Mahmoud Aljurf

Country flagSaudi Arabia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Chimeric Antigen Receptor T (CAR T) cell therapy targeting the CD19 antigen represents a significant advancement in the treatment of various subtypes of CD19-expressing hematologic malignancies. Nevertheless, the current commercial CAR T manufacturing process is intricate, time-consuming, and costly, involving a supply chain that initiates at the treating center with mononuclear cell apheresis, followed by cryopreservation and shipping to and from a centralized third-party manufacturing facility. This process can introduce treatment delays due to logistical requirements. We hypothesized that point-of-care (POC) manufacturing of CAR T cells could reduce vein to vein time which is one of the major challenges with commercial CAR T processes. This study presents the outcomes of large-scale, clinical-grade, in-house POC CAR T manufacturing, including assessments of transduction efficiency, vector copy number, phenotype, and effector function of CAR T cells. Utilizing the CliniMACS Prodigy system, we processed mononuclear cells from fresh leukapheresis harvests of healthy donors. The cells underwent automated processing and activation with TransAct, a polymeric nanomatrix activation reagent containing CD3/CD28-specific antibodies. Following activation, the cells were transduced and expanded in the Centricult-unit under stabilized conditions, with automated feeding and media exchange. For transduction, we employed the Miltenyi Lentigen third-generation lentiviral vector, which delivers a second-generation CD19 CAR construct with a 4-1BB costimulatory domain and TNFRSF19 transmembrane domain. Our POC manufacturing data demonstrated the successful generation of large-scale CAR T cells, sufficient to prepare multiple doses within a shortened production period of 9 days, followed by cryopreservation for quality control assessment and batch certification for patient infusion. The transduction efficiencies, phenotype, and function of the Lentigen CD19 CAR T cells were comparable to previously published procedures, with overall T-cell yields sufficient for therapeutic application. CAR expression was evaluated by flow cytometry and vector copy number. In-process testing ensured the quality and suitability of CAR T cells in terms of sterility and cell number for the desired dose preparations. The final product was also subjected for the assessment of any replicative competent lentivirus. CAR-mediated target cell killing was assessed via co-culture assays, and cytokine release was measured by ELISA. To evaluate the shelf life of the cryopreserved product, stability and viability were checked at approximately 6 and 12 months. Our results indicate that in-house POC manufacturing at King Faisal Specialist Hospital & Research Centre (KFSH&RC) enables regulatory-compliant production of CAR T cells, eliminating the need for third-party shipping logistics.

Year:

2024

This retrospective study evaluated 35 children (median age 5.2 years; range 0.4–18) with myelofibrosis (MF), including 33 with primary myelofibrosis and 2 with secondary myelofibrosis transplanted from matched sibling donor (MSD) ( n = 17) or non-MSD ( n = 18) between 2000 and 2022. Conditioning was usually chemotherapy-based ( n = 33) and myeloablative ( n = 32). Fifteen patients received bone marrow (BM), 14 haematopoietic cells (HC) from peripheral blood (PB), and 6 from cord blood (CB). Day +100 acute GvHD II–IV incidence was significantly lower after MSD-haematopoietic cell transplantation (MSD-HCT) than after non-MSD-HCT [18.8% (4.3–41.1) vs 58.8% (31–78.6); p = 0.01]. Six-year non-relapse mortality (NRM) was 18% (7.1–32.8), relapse incidence was 15.9% (5.6–30.9), progression-free survival (PFS) was 66.1% (47–79.7), GvHD-free relapse-free survival was 50% (30.6–66.7), and overall survival (OS) was 71.1% (51.4–84). Six-year PFS and OS were significantly higher after BM transplantation compared to HCT from other sources [85.1% (52.3–96.1) vs 50.8% (26.3–71), p = 0.03, and 90.9% (50.8–98.7) vs 54% (28.1–74.2), p = 0.01, respectively], whereas NRM was significantly lower [0% vs 32% (12.3–53.9); p = 0.02]. This first multicentre study on outcomes of allogeneic HCT in children with myelofibrosis proves feasibility and curative effect of transplantation in these children, suggests that bone marrow transplantation is associated with better outcomes, and indicates the need for further studies.

Year:

2024

In the setting of a learning collaborative, we conducted an international multicenter phase 2 clinical trial testing the hypothesis that nonmyeloablative–related haploidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy) will result in 2-year event-free survival (no graft failure or death) of at least 80%. A total of 70 participants were evaluable based on the conditioning protocol. Graft failure occurred in 8 of 70 (11.4%) and only in participants aged <18 years; all had autologous reconstitution. After a median follow-up of 2.4 years, the 2-year Kaplan-Meier–based probability of event-free survival was 82.6%. The 2-year overall survival was 94.1%, with no difference between children and adult participants. After excluding participants with graft failure (n = 8), participants with engraftment had median whole blood donor chimerism values at days +180 and +365 after transplant of 100% (n = 58), respectively, and 96.6% (57/59) were off immunosuppression 1 year after transplant. The 1-year grade 3 to 4 acute graft-versus-host disease (GVHD) rate was 10%, and the 2-year moderate–severe chronic GVHD rate was 10%. Five participants (7.1%) died from infectious complications. We demonstrate that nonmyeloablative haploidentical BMT with thiotepa and PTCy is a readily available curative therapy for most adults, even those with organ damage, compared to the more expensive myeloablative gene therapy and gene editing. Additional strategies are required for children to decrease graft failure rates. The trial was registered at www.clinicaltrials.gov as #NCT01850108.

Year:

2024

Background T-cell acute lymphoblastic leukemia (T-ALL) predominantly affects individuals in late childhood and young adulthood. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative modality particularly in the setting of poor risk genetics and/or persistent minimal residual disease. Limited studies have directly explored the impact of patient- and transplant-related factors on post-transplant outcomes in T-ALL. Methods Using a large dataset from the European Society for Blood and Marrow Transplantation registry, we identified 1907 adult T-ALL patients (70% male) who underwent their first allo-HSCT in first complete remission (CR1) from matched sibling donors (MSD; 45%), unrelated donors (UD; 43%) or haploidentical donors (12%) between 2010 and 2021. Results The median age at transplant was 33.4 years (18.1–75). The median follow up was 2.9 years. Most patients underwent total body irradiation (TBI)-based myeloablative conditioning (69%). The 2-year overall survival (OS) was 69.4%, and leukemia -free survival (LFS) was 62.1%. In multivariate analysis, advanced age at transplant negatively affected LFS (for each 10-year increment, HR = 1.11, p = 0.004), GVHD-free, relapse-free survival (GRFS) (HR = 1.06, p = 0.04), OS (HR = 1.12, p = 0.002), and non-relapse mortality (NRM) (HR = 1.23, p < 0.001). A later year of HSCT was associated with improved GFRS (For each 3-year increment, HR = 0.89, p < 0.001), OS (HR = 0.9, p = 0.02), and decreased NRM (HR = 0.82, p = 0.008). TBI improved LFS (HR = 0.79, p = 0.02), GRFS (HR = 0.83, p = 0.04), and relapse incidence (RI) (HR = 0.65, p < 0.001). Female-to-male transplant negatively affected GRFS (HR = 1.21, p = 0.02) and OS (HR = 1.23, p = 0.048). In vivo T-cell depletion significantly improved GFRS (HR = 0.74, p < 0.001). Conclusion This large study identified prognostic factors, such as age at transplant conditioning regimen, in influencing post-transplant in adult T-ALL patients undergoing allo-HSCT. Importantly, a significant improvement over time was noted. These findings hold great promise for new adapted treatment strategies and can serve as a benchmark for future studies in that setting.

Year:

2024

Introduction: Hematopoietic stem cell transplantation (HSCT) is a vital treatment for various hematological disorders. However, HSCT recipients face increased risks of infectious complications due to immunosuppression. Parasitic infections are a significant concern in this vulnerable population and can lead to substantial morbidity and mortality. This review examines parasitic infections in HSCT recipients, focusing on major infections affecting different organ systems, including intestinal parasites (Giardia spp., Entamoeba histolytica, and Cryptosporidium spp.), hematologic parasites (Plasmodium spp. and Babesia spp.), and tissue/visceral parasites (Toxoplasma gondii, Leishmania spp., and Trypanosoma cruzi). Methods: A systematic search of relevant literature was conducted and included studies up to August 2023. Databases included PubMed, Google Scholar, were queried using specific keywords related to parasitic infections in HSCT patients. The epidemiology, risk factors, clinical presentation, diagnostic methods, and treatment approaches for each infection were evaluated. Results and Conclusion: Knowing the epidemiology, risk factors, and clinical presentations are crucial for timely intervention and successful management. By emphasizing early detection, effective therapies, and the unique challenges posed by each of these infections, this review highlights the importance of tailored strategies for HSCT recipients. Future research can further refine management protocols to enhance care and outcomes for these patients.

Year:

2023

Collaborators (15)

Mohamad Mohty

-

FRANCE
View details

Eolia Brissot

Sorbonne Université

FRANCE
View details

Bernd Gruhn

Medical University Lausitz - Carl Thiem

GERMANY
View details

marc bierings

MD PHD Chief

Princess Maxima Center

NETHERLANDS
View details

James Connelly

Vanderbilt University Medical Center

UNITED STATES
View details

Michael R. DeBaun

J.C. Peterson Endowed Chair in Pediatric Pulmonology

Vanderbilt University Medical Center

UNITED STATES
View details

Erfan Nur

-

NETHERLANDS
View details

Zinaida Perić

Associate Professor

University in Rijeka

CROATIA
View details

KRZYSZTOF KALWAK

MD, PhD, Prof

Wroclaw Medical University

POLAND
View details

Adetola A. Kassim

-

UNITED STATES
View details

Antonio Pérez-Martínez

La Paz University Hospital

SPAIN
View details

Fabio Ciceri

Associate Professor of Hematology

Vita-Salute San Raffaele University

ITALY
View details

Jacek Wachowiak

Director / Professor

Poznan University of Medical Sciences

POLAND
View details

Gerard Socie

-

FRANCE
View details

Biljana Horn

University of Florida

UNITED STATES
View details